Pfizer’s vaccine for Omicron, BQ. Antibody large in 1.1 | Reuters

The U.S. pharmaceutical giant Pfizer and the German biopharmaceutical company Biontech announced on the 18th that the new coronavirus Omicron strain-derived BQ. It was more than twice as high as the first doses of the two companies’ vaccines, the company said. This photo was taken in November 2021. (Reuters/Dado Ruvic/Illustration)

(Reuters) – U.S. pharmaceutical giant Pfizer and German biopharmaceutical company Biontech said on Monday that their jointly developed Omicron strain-derived BQ.1.1 vaccine will be administered to people over the age of 55. It said that it increased the total antibody by nearly 9 times, which is more than about 2 times higher than when the first vaccines of both companies were administered.

Two types of vaccines were administered to about 40 people each and compared. Published in the online data archive “bioRxiv”.

In the United States, BQ. Derivative infections related to BQ.1, such as 1.1, are thought to have reached nearly half of all corona infections, and are expected to spread in Europe this winter.